Table 3. Time to progression and experience of endocrine complications on nivolumab treatment.

	B	SE	Wald	Df	p	Exp(B)	95% CI dla Exp(B)
							LCI	UCI
Time-dependent covariance variable	-0,264	0,467	0,318	1	0,573	0,768	0,308	1,920
Model summary	-2LLg = 179,922; χ 2 = 0,325; df = 1; p = 0,569